Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16N4O2.2ClH |
Molecular Weight | 381.256 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN1N(C(=O)C(NC(=O)C2=CN=CC=C2)=C1C)C3=CC=CC=C3
InChI
InChIKey=KOJCCAVPCPSQAR-UHFFFAOYSA-N
InChI=1S/C17H16N4O2.2ClH/c1-12-15(19-16(22)13-7-6-10-18-11-13)17(23)21(20(12)2)14-8-4-3-5-9-14;;/h3-11H,1-2H3,(H,19,22);2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H16N4O2 |
Molecular Weight | 308.3345 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14133613Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Nifenazone is a drug that has been used as an analgesic for a number of rheumatic conditions. Later it was shown that nifenazone is not of significant value in the therapy of the chronic rheumatic disorders and that side-effects may be expected to occur, particularly in those patients who give a history of abnormal reactions to phenylbutazone and oxyphenbutazone.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
TRIAL OF NIFENAZONE ("THYLIN"). | 1964 Jun 13 |
|
Evaluation of liver function during administration of nifenazone in rheumatic disease on the basis of serum protein studies and enzyme tests. | 1972 Apr-Jun |
|
The solvatochromic, spectral, and geometrical properties of nifenazone: a DFT/TD-DFT and experimental study. | 2014 Aug 7 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
750 - 2,000 mg. daily, orally in divided dosage.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:25:03 GMT 2023
by
admin
on
Sat Dec 16 08:25:03 GMT 2023
|
Record UNII |
AJ9RXT13PC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
51658-08-3
Created by
admin on Sat Dec 16 08:25:03 GMT 2023 , Edited by admin on Sat Dec 16 08:25:03 GMT 2023
|
PRIMARY | |||
|
71587162
Created by
admin on Sat Dec 16 08:25:03 GMT 2023 , Edited by admin on Sat Dec 16 08:25:03 GMT 2023
|
PRIMARY | |||
|
AJ9RXT13PC
Created by
admin on Sat Dec 16 08:25:03 GMT 2023 , Edited by admin on Sat Dec 16 08:25:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |